Supplementary Material

Supplementary Methods

Survey Design and Sample Size

The study was designed as a cross-sectional assessment. The study was reviewed by the Texas Tech University Health Sciences Center Institutional Review Board and was exempt from requiring participant consent due to the anonymity of the survey answers. The survey questions were developed and reviewed by a team of pediatric nephrologists. The questions were grounded on a thorough literature review of qualitative and quantitative studies of adolescent females and women's health topics. The survey was first discussed and tested within a small group of expert nephrologists that care for adolescent females and young adult females. In 2018, the survey was presented to a larger group at a Pediatric Nephrology Research Consortium (PNRC) meeting. The survey was distributed electronically from April to September 2019 using Qualtrics Online Survey Platform to all 305 adult nephrologists and pediatric nephrologists (from 88 participating centers in the U.S. and Canada) who were members of the PNRC. Reminder emails were sent monthly. Survey submissions were voluntary and anonymous. The survey included a total of 19 questions (Supplementary Figure 1). The first questions addressed provider characteristics, including: demographics (age and gender); years in practice as a nephrologist; practice location (response options in Table 1); prior formal training in obstetric nephrology and/or women's health. Providers were then asked to report how frequently they documented adolescents' ages at menarche, menstrual cycle history and patterns, contraceptive use, sexual activity, history of sexually transmitted disease, discussions about fetotoxicity or infertility risks associated with specific medications, and discussions about family planning. These responses were rated using a Likert scale, on a spectrum of "Never" to "Always". Finally, provider confidence managing reproductive health and pregnancy-related issues in adolescent females with CKD/ESRD were assessed using a Likert Scale, on a spectrum of "Not at all" to "Very Confident".

Data Analysis

All survey responses were summarized and analyzed using descriptive statistics (percentages or frequencies) via the Qualtrics Data Analysis Platform (https://www.qualtrics.com/).

Survey

This survey is for Nephrologists who take care of adolescents (12-18 years of age). The purpose of this survey is to gain a better understanding of the reproductive care provided to teenage patients by Nephrology providers in day-to day practice. You are requested to take this survey because you are a nephrology provider. Please answer to the best of your ability.

Part A: Provider information

Age
Sex (please circle) Male Female Prefer not to answer
Country of nephrology practice:
How many years have you been in practice:
In what Country did you complete your Nephrology training?
Current practice setting:
□ Academic/University
□ Hybrid
☐ Still in training
□ Other
What is the clinical scope of your practice? (Check all that apply)
□ Pediatric nephrology
☐ Adult nephrology
What percent of your job is dedicated to the clinical care of patients?
\Box 0-24%
□ 25-49%
□ 50-74%

	75-100%
	percentage of your patients are adolescents? 0-24% 25-49% 50-74% 75-100%
	ur nephrology training include any formal training in Obstetric nephrology Women's health : Clinical Survey
At	what age do you start doing Tanner staging (years)? ow often do you do Tanner staging?
	never
	yearly
	every 6 months
	every visit
	intermittently/no set schedule
	only when required for research study

Please tell us how frequently you **asses and document** in the chart the following when evaluating an adolescent female in clinic?

	Never	Rarely	Sometimes	Often	Always
Age of first menstrual cycle					
2. Pregnancy history					
3. History of pregnancy termination/loss					
4. LMP Date					
5. Prior conception use					
6. Prior consensual or nonconsensual sexual Activity					

Preference (male/female/both) 8. Number of Sexual Partners 9. STD/STIs 10. Documentation of a discussion on the risk of fetotoxity with ACEi/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility-preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	7. Sexual Partner			
(male/female/both) 8. Number of Sexual Partners 9. STD/STIs 10. Documentation of a discussion on the risk of fetotoxity with ACEI/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility-preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
8. Number of Sexual Partners 9. STD/STIs 10. Documentation of a discussion on the risk of fetotoxity with ACEi/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility-preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
Partners 9. STD/STIs 10. Documentation of a discussion on the risk of fetotoxity with ACEi/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility-preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	` ′			
9. STD/STIs 10. Documentation of a discussion on the risk of fetotoxity with ACEi/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility-preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
10. Documentation of a discussion on the risk of fetotoxity with ACEi/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
a discussion on the risk of fetotoxity with ACEi/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility-preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	9. STD/STIs			
risk of fetotoxity with ACEi/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	10. Documentation of			
with ACEi/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	a discussion on the			
with ACEi/ARBS or mycophenolate use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	risk of fetotoxity			
use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
use 11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	or mycophenolate			
11. Document a negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	· -			
negative pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
pregnancy test before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
before starting a fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
fetotoxic medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
medication 12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility-preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
12. Discuss the risk of infertility with cyclophosphamide 13. Discuss fertility-preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
infertility with cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
cyclophosphamide 13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
13. Discuss fertility- preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
preserving options (hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
(hormonal ovarian suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
suppression, oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for				
oocyte cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	(hormonal ovarian			
cryopreservation) with exposure to cyclophosphamide 14. Discussion on patient's desire for	suppression,			
with exposure to cyclophosphamide 14. Discussion on patient's desire for	oocyte			
cyclophosphamide 14. Discussion on patient's desire for	cryopreservation)			
cyclophosphamide 14. Discussion on patient's desire for	with exposure to			
14. Discussion on patient's desire for				
	patient's desire for			
	future pregnancy			

Please indicate your **level of confidence** in your ability to care for adolescents with CKD/ESRD in the following situations.

	A) Not at all	B) Somewhat confident	C) Confident	D) Very confident
Manage menstrual disorders				
2. Determining need for fertility preservation				
3. Assess bone health				

4. Counsel on fetal outcomes by CKD stage		
5. Counsel on fetotoxicity related to immunosuppression		
6. Discuss the risks and benefits of contraception		

Please indicate your **level of confidence** in your ability to counsel an adolescent on the following contraception options.

	A)	B)	C)	D)
	Not at all	Somewhat	Confident	Very
		confident		confident
 Oral contraceptive pills 				
2. Injectable Hormonal				
Contraception				
3. IUD				
4. Contraceptive Implants				
5. Vaginal Ring				
6. Skin Patch				
7. Barrier Devices				
8. Contraceptive				
foam/jelly/inserts/sponges				

	a average, how many adolescents of childbearing age with kidney disease have you unseled on contraception in the last 12 months?
	0
	Less than one per month
	1-2 per month
	3-4 per month
	5 or more per month
Who	prescribes contraception for your adolescent patients? (Check all that apply)
	I do
	Adolescent medicine
	Gynecology
	Pediatrician/primary care physician
	Other

On average, how many pregnant adolescents have you cared for in the last 12 months?

Who takes care of pregnant adolescents in your practice?
☐ I refer to adult nephrology
☐ I keep them and manage them myself
☐ I co-manage with an obstetrics doctor
□ Other
If one of your patients gets pregnant, and you refer them to adult nephrology, when will they return to your pediatric-focused practice?
□ Never – they continue to follow with adult nephrology
□ Post-delivery once cleared by OB
□ Other

Supplementary References

b. 1-2c. 3-4

d. 5 or more

- S1. Isaacs, J.N. and M.D. Creinin, *Miscommunication between healthcare providers and patients may result in unplanned pregnancies*. Contraception, 2003. **68**(5): p. 373-6.
- S2. Schreiber, C.A., et al., *Training and attitudes about contraceptive management across primary care specialties: a survey of graduating residents.* Contraception, 2006. **73**(6): p. 618-22.
- S3. Papas, B.A., et al., Contraceptive counseling among pediatric primary care providers in Western Pennsylvania: A survey-based study. SAGE Open Med, 2017. 5: p. 2050312117730244.
- S4. Swanson, K.J., D.R. Gossett, and M. Fournier, *Pediatricians' beliefs and prescribing patterns of adolescent contraception: a provider survey.* J Pediatr Adolesc Gynecol, 2013. **26**(6): p. 340-5.
- S5. Wilson, S.F., W. Strohsnitter, and L. Baecher-Lind, *Practices and perceptions among pediatricians regarding adolescent contraception with emphasis on intrauterine contraception*. J Pediatr Adolesc Gynecol, 2013. **26**(5): p. 281-4.
- S6. Martinez, G., J. Abma, and C. Copen, *Educating teenagers about sex in the United States*. NCHS Data Brief, 2010(44): p. 1-8.
- S7. Allen, S. and E. Barlow, *Long-Acting Reversible Contraception: An Essential Guide for Pediatric Primary Care Providers*. Pediatr Clin North Am, 2017. **64**(2): p. 359-369.
- S8. Ott, M.A., G.S. Sucato, and A. Committee on, *Contraception for adolescents*. Pediatrics, 2014. **134**(4): p. e1257-81.
- S9. Olson, E.M., et al., *Health Care Barriers to Provision of Long-Acting Reversible Contraception in Wisconsin.* WMJ, 2018. **117**(4): p. 149-155.

- S10. Rubin, S.E., K. Davis, and M.D. McKee, *New york city physicians' views of providing long-acting reversible contraception to adolescents*. Ann Fam Med, 2013. **11**(2): p. 130-6.
- S11. Rubin, S.E., et al., *Determinants of intrauterine contraception provision among US family physicians: a national survey of knowledge, attitudes and practice.* Contraception, 2011. **83**(5): p. 472-8.
- S12. Stubbs, E. and A. Schamp, *The evidence is in. Why are IUDs still out?: family physicians' perceptions of risk and indications.* Can Fam Physician, 2008. **54**(4): p. 560-6.
- S13. Tyler, C.P., et al., *Health care provider attitudes and practices related to intrauterine devices for nulliparous women.* Obstet Gynecol, 2012. **119**(4): p. 762-71.
- S14. American Academy of Pediatrics Committee on, A., et al., *Menstruation in girls and adolescents: using the menstrual cycle as a vital sign.* Pediatrics, 2006. **118**(5): p. 2245-50.
- S15. McShane, M., et al., *Menstrual History-Taking at Annual Well Visits for Adolescent Girls*. J Pediatr Adolesc Gynecol, 2018. **31**(6): p. 566-570.
- S16. Tomlin, K., L. Mirea, and A. Williamson, *Pediatric and Gynecologic Rates of Documentation of Last Menstrual Period in Female Adolescents*. J Pediatr Adolesc Gynecol, 2018. **31**(4): p. 346-349.
- S17. Nur Azurah, A.G., et al., *The quality of life of adolescents with menstrual problems*. J Pediatr Adolesc Gynecol, 2013. **26**(2): p. 102-8.
- S18. Williams, C.E. and S.M. Creighton, *Menstrual disorders in adolescents: review of current practice*. Horm Res Paediatr, 2012. **78**(3): p. 135-43.
- S19. Hladunewich, M.A., N. Melamed, and K. Bramham, *Pregnancy across the spectrum of chronic kidney disease*. Kidney Int, 2016. **89**(5): p. 995-1007.
- S20. Piccoli, G.B., et al., Pregnancy in Chronic Kidney Disease: Need for Higher Awareness. A Pragmatic Review Focused on What Could Be Improved in the Different CKD Stages and Phases. J Clin Med, 2018. 7(11).
- S21. Hefley, S., L Vasylyeva, T., Salguero, M., Al-Humaish, S., Cutts, K., & Smalligan, R. (2020). Gender of internal medicine resident impacts cancer preventive care for women . Journal of Internal Medicine: Science & Art, 1(1), 11 15.

Study Limitations

While this study provides valuable information on the frequency of documenting and/or discussing women's health issues, and level of confidence in managing women's health problems of nephrologists caring for adolescent female patients with CKD, it has several limitations. Firstly, this study only shows the reported activities of providers, which does not necessarily reflect the actual practice of providers in these settings. Furthermore, asking providers to describe prior

practices might have resulted in recall bias. Moreover, provider personal beliefs and the era of their medical education may also result in potential biases in how they deliver reproductive care to adolescents.

Also, although responses were anonymous, we cannot exclude the possibility of either inaccurate or untrue responses. Nevertheless, the overall sub-optimal practices reported by these providers suggest that the providers likely did not falsify their responses to avoid critique. We also did not specifically ask how many female adolescents the providers care for each year, rather the proportion of adolescents that make up their practice. Accordingly, patient numbers might have been very small for some of the providers. Since a majority of the providers were members of an academic consortium, and most practiced in an academic setting, practices reported in this study additionally might not reflect practices occurring in community or rural settings. Finally, we did not examine potential solutions to the barriers in knowledge, confidence, and competence identified in this study, but we hope to do this as a focus of future work that could include an educational symposium and/or a future publication on this important topic.

Abbreviations

AAP American Academy of Pediatrics

CKD Chronic Kidney Disease

IUD Intrauterine Device

LARC Long-Acting Reversible Contraceptive

LMP Last Menstrual Period

STI Sexually Transmitted Infection

Disclosures

Dr. Almaani consults with Aurinia Pharmaceuticals, outside the submitted work. All other authors declare no conflicts of interests or competing interests

Acknowledgements

The authors would like to thank The Laura W. Bush Institute for Women's Health for supporting publication fees for this study.